Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for bradykinesia in Parkinson's disease
IRCT20190207042651N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of memantine in Parkinson's disease (PD) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: bradykinesia. Started Jan 2018; status: completed.
02
Drugs
memantine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on IRCT20190207042651N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190207042651N1.